initi price target
one week love week hate
steadi biopharma demand impli anoth year msd growth
notabl wrong respect share
belief scrutini drug price would slow pharma capital-expenditure mute
core growth realli come fruition moreov remind
pend synchron global recess materi disloc
pharma demand highli unfavor fx movement thing tend
pretti steadi see reason growth derail head
macro driver skew favor slight down-tick
pharma relat demand met cyclic bia industri
furthermor first time sever year fx appear tailwind
ep erod nearli last sever year
tax reform major swing factor alreadi factor valuat
one add benefit repatri ep may actual see
materi up-tick growth albeit one time natur magnitud
benefit depend sever factor key swing element ep
upsid much ou cash use repurchas vs
debt pay-down gross debt elev given trap cash time
execut model assum benefit accru time
vs sizeabl asr earli neutral share
current pretti simpli think market effici
multipl expand current alreadi price fair amount
ep upsid thu would need see one aggress
scenario yield rel upsid given dynam see
risk reward balanc thu initi share rate
thing watch repatri strategi pharma capital-expenditure growth
degre fx tailwind
debat pharma capital-expenditure cycl
right level omx ex-fx medium term big deal tax
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate pt
translat ebitda vs average
price-to-earnings basi translat vs average
downsid risk potenti synchron global deceler
pmi post recent expans yield averag core growth
rate challeng pharma capital-expenditure due renew fear drug
price coupl pain gener deflat harm ou budget
unfavor fx dynam challeng magnitud gross margin
expans limit overal omx potenti oi growth
product introduct sizeabl up-tick biolog discoveri activ
market share gain across portfolio given renew focu
notabl introduct high-end ms area weak
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
initi pt
one week love week hate
last page report import disclosur regard stock report
tabl content
compani overview king chromatographi
debat pharma capital-expenditure cycl
debat right level omx ex-fx medium term
debat big deal tax reform repatri
financi model tax reform deal ep
point differenti vs st
iv valuat risk volatil premium
 conclus initi effici market theori
water milford king chromatographi
global leader separ scienc measur
special tool provid distinct focu high-
end instrument chemistri servic softwar
lc ms thermal analysi
differenti challeng market correctli
price massiv repatri opportun post reform
rate valuat pt pt
ebitda vs average
price-to-earnings vs average
risk synchron macro slowdown capit
equip coupl pharma paus due drug price
new experienc management w/ solid execut histori
previous evp rtg
previous libbey
debat pharma capital-expenditure cycl
strong year pharma moder msd
caus concern durat current capital-expenditure cycl
howev caus slowdown appear tempor
given macro st like assum msd pharma
larger pharma favor friendli european
india gst caus short-term pushout custom
compli w/ new system law
gener mix bag w/ bigger compani
halt invest us strong w/
share price core growth
given current macro believ st assum
flat slightli pharma
msd growth pharma seem appropri w/ capital-expenditure like lsd rang
debat right level omx ex-fx medium term
omx deceler follow bp
caus question futur omx opportun
lead solid oper incom growth mt
despit feel tap modest omx appear reason assum fx stabl
debat big deal tax reform repatri
massiv ou cash hold
histor tie favor tax structur
massiv ep upsid repatri w/ modest leverag
howev futur inflect repo bake mult
assum ou cash use pay revolv rest repo
ou repo
situat bear monitor benefit repatri like bake share
model summari point differenti vs street
swing factor capital-expenditure trajectori fx tailwind vs headwind china india growth
point differenti
growth
remain stabl
opex
boost per annum
valuat normal
one time boost natur
futur balanc street construct pace repurchas determin ep upsid
million except per share data fy end decemb instrument organ gp less total op less ep share inc net inc price-to-earnings prem disc januari
valuat elev reflect upsid potenti repatri
rel metric normal time benefit repurchas re-leverag flow incom statement
risk point balanc risk reward profil volatil ep profil vs effici multipl step-up
potenti synchron global deceler pmi post recent expans yield averag core growth rate
challeng pharma capital-expenditure due renew fear drug price coupl pain gener deflat harm ou budget
unfavor fx dynam challeng magnitud gross margin expans limit overal omx potenti oi growth
pharma capital-expenditure notabl reacceler given either key new product introduct sizeabl up-tick biolog discoveri activ
market share gain across portfolio given renew focu notabl introduct high-end ms area weak
dcf valuat yield price
dcf deriv pt impli termin growth rate impli ebitda multipl
assumpt underli dcf valuat methodolog
year ebita margin assumpt
termin ebitda multipl
tax rate
wacc base beta risk free rate cost debt
assumpt impli termin growth rate
discount ebitda termin free flow enterpris total valu valu per perpetu growth valu enterpris enterpris valu januari
conclus initi pt return
remark predict ep trajectori boost repatri market effici win
notabl wrong respect share belief scrutini
drug price would slow pharma capital-expenditure mute core growth realli come fruition
moreov remind pend synchron global recess materi disloc
pharma demand highli unfavor fx movement thing tend pretti steadi
see reason growth derail head macro driver skew favor
slight down-tick pharma relat demand met cyclic bia industri
furthermor first time sever year fx appear tailwind ep
erod nearli last sever year given unfavor movement
one add benefit repatri ep may actual see materi up-tick
growth albeit one time natur magnitud benefit depend sever factor
key swing element ep upsid much ou cash use repurchas
vs debt pay-down gross debt elev given trap cash time execut
model assum benefit accru time vs sizeabl asr earli
neutral share current pretti simpli think market effici
multipl expand current alreadi price fair amount ep upsid
thu would need see one aggress scenario yield rel upsid
given dynam see risk reward balanc thu initi share rate
thing watch repatri strategi pharma capital-expenditure growth degre fx tailwind
pleas feel free reach question follow-up
medic suppli devic
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst ross muken vijay kumar luke sergott primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research
